Serum and bile biomarkers for cholangiocarcinoma

Current Opinion in Gastroenterology

Volumn 25, Issue 3, 2009, Pages 279-284

  Alvaro, Domenico ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biliary biomarkers; Cholangiocarcinoma; Primitive sclerosing cholangitis; Proteomic; Serum biomarkers

Indexed keywords

AMYLASE; BIOLOGICAL MARKER; CYTOKERATIN 19 FRAGMENT; CYTOKINE; ELASTASE; ENZYME; GROWTH FACTOR; INTERLEUKIN 6; MINICHROMOSOME MAINTENANCE PROTEIN; MUCIN 4; MUCIN 5AC; SOMATOMEDIN C; TRYPSINOGEN; TUMOR MARKER;

BENIGN TUMOR; BILE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; HUMAN; LYMPHOCYTE COUNT; MALIGNANT NEOPLASTIC DISEASE; PANCREAS CANCER; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; PROTEOMICS; REVIEW; SERUM; THROMBOCYTE COUNT;

BILE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 67651096190     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328325a894     Document Type: Review

References (33)

1. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008; 48:308-321. An excellent and extensive review on the modern aspects of the pathogenetic and clinical aspects of CCA. (Pubitemid 351975555)
2. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis 2008; 12:131-150.
3. Khan SA, Miras A, Pelling M, Taylor-Robinson SD. Cholangiocarcinoma and its management. Gut 2007; 56:1755-1756.
4. Patel T, Singh P. Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr Opin Gastroenterol 2007; 23:317-323. (Pubitemid 46573149)
5. Yachimski P, Pratt DS. Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 2008; 42:178-190. An excellent review on the natural history, treatment and strategies of CCA in high-risk patients.
6. Morris-Stiff G, Bhati C, Olliff S, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience. Dig Surg 2008; 25:126-132. This study describes the prevalence and outcome of CCA arising in patients with PSC.
7. Schulick RD. Primary sclerosing cholangitis: detection of cancer in strictures. J Gastrointest Surg 2008; 12:420-422.
8. Ong SL, Sachdeva A, Garcea G, et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci 2008; 53:3213-3217.
9. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008; 48:1106-1117. The authors proposed the combination of serum carbohydrate antigen 19-29 (cutoff value of 20 U/ml) and abdominal ultrasound at 12-month intervals as useful strategy for screening/surveillance of CCA in PSC.
10. Yubin L, Chihua F, Zhixiang J, et al. Surgical management and prognostic factors of hilar cholangiocarcinoma: experience with 115 cases in China. Ann Surg Oncol 2008; 15:2113-2119.
11. Kitiyakara T, Chapman RW. Chemoprevention and screening in primary sclerosing cholangitis. Postgrad Med J 2008; 84:228-237. This review summarizes the incidence of malignancies in patients with PSC and discusses potential strategies for its early detection.
12. Tischendorf JJ, Geier A, Trautwein C. Current diagnosis and management of primary sclerosing cholangitis. Liver Transpl 2008; 14:735-746. (Pubitemid 351895502)
13. Cheon YK, Cho YD, Moon JH, et al. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol 2007; 102:2164-2170. This study describes that the elevation of IL-6 serum has a good sensitivity and specificity for CCA and that IL-6 decreased after photodynamic therapy. This observation may have implications in terms of diagnosis as well in the evaluation of response to treatment.
14. Smith RA, Ghaneh P, Sutton R, et al. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg 2008; 12:1422-1428.
15. Smith RA, Bosonnet L, Ghaneh P, et al. The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery 2008; 143:658-666.
16. Lempinen M, Isoniemi H, Mäkisalo H, et al. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol 2007; 47:677-683. In this study, serum trypsinogen-2 discriminates between PSC with or without CCA and was unaffected by the severity of cholestasis suggesting that this marker should be tested for the surveillance of patients with PSC.
17. Duraisamy S, Ramasamy S, Kharbanda S, et al. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16. Gene 2006; 373:28-34.
18. Bamrungphon W, Prempracha N, Bunchu N, et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett 2007; 247:301-308. The authors developed a sandwich ELISA of serum MUC5AC, which seems promising for the diagnosis and monitoring of CCA patients.
19. Matull WR, Andreola F, Loh A, et al. MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. Br J Cancer 2008; 98:1675-1681. This study indicates that biliary MUC4 and serum MUC5AC are highly specific CCA-associated mucins with prognostic values, although the sensitivity is not currently satisfactory.
20. Uenishi T, Yamazaki O, Tanaka H, et al. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2008; 15:583-589. (Pubitemid 351643031)
21. Bonney GK, Craven RA, Prasad R, et al. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol 2008; 9:149-158. An excellent review focusing on the recent advances on proteomic techniques applied to identify CCA biomarkers.
22. Liu L, Wang J, Liu B, Dai S, et al. Serum levels of variants of transthyretin downregulation in cholangiocarcinoma. J Cell Biochem 2008; 104:745-755. (Pubitemid 351830826)
23. Scarlett CJ, Saxby AJ, Nielsen A, et al. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Hepatology 2006; 44:658-666. (Pubitemid 44433722)
24. Alvaro D, Mancino MG. New insights on the molecular and cell biology of human cholangiopathies. Mol Aspects Med 2008; 29:50-57.
25. Mancino A, Mancino MG, Glaser SS, et al. Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig Liver Dis 2009; 41:156-163.
26. Alvaro D, Mancino MG, Glaser S, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 2007; 132:415-431. (Pubitemid 46108729)
27. Alvaro D, Barbaro B, Franchitto A, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol 2006; 169:877-888. (Pubitemid 44411954)
28. Alvaro D, Macarri G, Mancino MG, et al. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann Intern Med 2007; 2:451-459. This study demonstrated that bile IGF1 levels is absolutely sensitive and specific for extrahepatic CCA suggesting a role of this biomarkers in the differential diagnosis of patients submitted to ERCP for obstructive cholestasis.
29. Nishino R, Honda M, Yamashita T, et al. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol 2008; 49:207-216.
30. Chen CY, Tsai WL, Wu HC, et al. Diagnostic role of biliary pancreatic elastase for cholangiocarcinoma in patients with cholestasis. Clin Chim Acta 2008; 390:82-89. The study indicates that ratio of pancreatic elastase/amylase in bile distinguish malignant from benign causes of biliary obstruction with a good sensitivity and specificity.
31. Ayaru L, Stoeber K, Webster GJ, et al. Diagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance protein 5 in bile aspirates. Br J Cancer 2008; 6:1548-1554. (Pubitemid 351652335)
32. Chen B, Dong JQ, Chen YJ, et al. Two-dimensional electrophoresis for comparative proteomic analysis of human bile. Hepatobiliary Pancreat Dis Int 2007; 6:402-406. (Pubitemid 47288125)
33. Albiin N, Smith IC, Arnelo U, et al. Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiol 2008; 18:1-8.